Crowdly
Add to Chrome
Eli Lilly decided to test all four lead compounds in Phase I clinical trials an...
✅ The verified answer to this question is available below. Our community-reviewed solutions help you understand the material better.
Eli Lilly decided to test all four lead compounds in Phase I clinical trials and the following pharmacokinetic parameters were determined.
Table 4: Pharmacokinetic properties of lead compounds as determined in Phase I clinical trials
| Plasma half-life (hours) | Volume of distribution (L/kg) | Metabolic pathway | Adverse effects |
EL-10 | 33 | 25 | CYP3A4, CYP2C9 | Arrhythmia |
EL-11 | 98 | 40 | CYP1A2, CYP2D6, CYP3A4, CYP2D6 | Arrhythmia |
EL-12 | 24 | 20 | CYP2C19 | Arrhythmia |
EL-13 | 9 | 7 | CYP3A4 | Arrhythmia |
Based on the data provided in Table 4, which of the compounds would be predicted to have the highest lipophilicity?
❌
✅
❌
❌